Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
'Zootopia 2' movie reviews: A heartwarming, hysterical and earnest 'ode to community' - 2Blue Origin safely launches wheelchair user to space and back
- 3Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- 4Creative Style: 10 Architects Reclassifying the Business
- 5A mom stopped giving her kids snacks — and sparked a debate about eating habits
- 5 Breakout Stars in Ongoing television Series
- Transform the daily grind to make life more interesting – a philosopher shares 3 strategies to help you attain the good life
- 7 Strange Devices to Make Your Party Stick Out!
- Far-right leader Le Pen to attend Brigitte Bardot's funeral
- Step by step instructions to Think about Disc Rates Across Various Banks
- Top 15 Online Entertainment Stages for Individual Marking
- California is completely free of drought for the first time in 25 years
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Far reaching Guide
- These 3 Nail-Free Finds Completely Transformed My Drab Bathroom
